Screener
Alnylam Pharmaceuticals ALNY Available For Sale Securities Debt Securities Current
Available For Sale Securities Debt Securities Current at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,708,318 | $1,657,250 |
| Marketable debt securities | 1,599,829 | 1,251,234 |
| Accounts receivable, net | 912,739 | 777,567 |
| Inventory | 97,110 | 82,719 |
| Prepaid expenses and other current assets | 302,176 | 281,892 |
| Total current assets | 4,620,172 | 4,050,662 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's available for sale securities debt securities current?
- Alnylam Pharmaceuticals (ALNY) reported available for sale securities debt securities current of $1.6B in Q2 2026.
- How has Alnylam Pharmaceuticals's available for sale securities debt securities current changed year-over-year?
- Alnylam Pharmaceuticals's available for sale securities debt securities current decreased by 8.3% year-over-year, from $1.74B to $1.6B.
- What is the long-term trend for Alnylam Pharmaceuticals's available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's available for sale securities debt securities current has grown at a -1.3% compound annual growth rate (CAGR), from $1.33B to $1.25B.
Ask your AI about Alnylam Pharmaceuticals's available for sale securities debt securities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude